Gene Transfer for Neovascular Age-Related Macular Degeneration
- 1 May 2011
- journal article
- review article
- Published by SAGE Publications in Human Gene Therapy
- Vol. 22 (5) , 523-529
Abstract
Age-related macular degeneration (AMD) is a complex disease that has two phases: a degenerative phase often referred to as nonneovascular AMD (non-NVAMD) or dry AMD and a phase dominated by growth of new blood vessels in the subretinal space, referred to as NVAMD or wet AMD. Advances in the understanding of the molecular pathogenesis of NVAMD have led to new drug therapies that have provided major benefits to patients. However, those treatments require frequent intraocular injections that in many patients must be continued indefinitely to maintain visual benefits. Gene transfer to augment expression of endogenous antiangiogenic proteins is an alternative approach that has the potential to provide long-term stability in patients with NVAMD. Studies in animal models that mimic aspects of NVAMD have identified several possible transgenes, and a clinical trial in patients with advanced NVAMD has suggested that the approach may be feasible. Many important questions remain, but the rationale and preliminary data are compelling. The results of two ongoing clinical trials may answer several of the questions and help direct future research.Keywords
This publication has 55 references indexed in Scilit:
- Preclinical Safety Evaluation of AAV2-sFLT01— A Gene Therapy for Age-related Macular DegenerationMolecular Therapy, 2011
- Inhibition of Choroidal Neovascularization in a Nonhuman Primate Model by Intravitreal Administration of an AAV2 Vector Expressing a Novel Anti-VEGF MoleculeMolecular Therapy, 2011
- An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillarisProceedings of the National Academy of Sciences, 2009
- Endogenous VEGF Is Required for Visual Function: Evidence for a Survival Role on Müller Cells and PhotoreceptorsPLOS ONE, 2008
- Prolonged blockade of VEGF family members does not cause identifiable damage to retinal neurons or vesselsJournal of Cellular Physiology, 2008
- Vascular Endothelial Growth Factor-A Is a Survival Factor for Retinal Neurons and a Critical Neuroprotectant during the Adaptive Response to Ischemic InjuryThe American Journal of Pathology, 2007
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Long-term Evaluation of AAV-Mediated sFlt-1 Gene Therapy for Ocular Neovascularization in Mice and MonkeysMolecular Therapy, 2005
- Complement Factor H Polymorphism in Age-Related Macular DegenerationScience, 2005
- Identification of a Natural Soluble Form of the Vascular Endothelial Growth Factor Receptor, FLT-1, and Its Heterodimerization with KDRBiochemical and Biophysical Research Communications, 1996